COFCO Biotechnology Bilan de santé

Santé financière contrôle des critères 5/6

COFCO Biotechnology possède un total de capitaux propres de CN¥10.9B et une dette totale de CN¥3.9B, ce qui porte son ratio d'endettement à 35.4%. Son actif total et son passif total sont CN¥17.2B et de CN¥6.3B.

Informations clés

35.4%

Ratio d'endettement

CN¥3.86b

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	CN¥1.67b
Fonds propres	CN¥10.90b
Total du passif	CN¥6.28b
Total des actifs	CN¥17.18b

Mises à jour récentes de la santé financière

We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt

Sep 30

COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt

Jun 03

Recent updates

COFCO Biotechnology Co., Ltd. (SZSE:000930) Surges 39% Yet Its Low P/S Is No Reason For Excitement

Oct 14

We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt

Sep 30

COFCO Biotechnology Co., Ltd. (SZSE:000930) Looks Inexpensive But Perhaps Not Attractive Enough

Jul 17

COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt

Jun 03

Returns On Capital Signal Tricky Times Ahead For COFCO Biotechnology (SZSE:000930)

Apr 17

COFCO Biotechnology Co., Ltd.'s (SZSE:000930) Price Is Right But Growth Is Lacking

Mar 07

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 000930 ( CN¥6.8B ) dépassent ses passifs à court terme ( CN¥5.7B ).

Passif à long terme: Les actifs à court terme de 000930 ( CN¥6.8B ) dépassent ses passifs à long terme ( CN¥618.2M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 000930 ( 20.1% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de 000930 a été réduit de 49.6% à 35.4% au cours des 5 dernières années.

Couverture de la dette: La dette de 000930 est bien couverte par le flux de trésorerie opérationnel ( 20.5% ).

Couverture des intérêts: Données insuffisantes pour déterminer si les paiements d'intérêts de 000930 sur sa dette sont bien couverts par l'EBIT.

COFCO Biotechnology Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt

COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt

Recent updates

Third quarter 2024 earnings released: CN¥0.028 loss per share (vs CN¥0.001 profit in 3Q 2023)

COFCO Biotechnology Co., Ltd. (SZSE:000930) Surges 39% Yet Its Low P/S Is No Reason For Excitement

COFCO Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt

COFCO Biotechnology Co., Ltd. Announces Board Changes

Second quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.18 loss in 2Q 2023)

COFCO Biotechnology Co., Ltd. (SZSE:000930) Looks Inexpensive But Perhaps Not Attractive Enough

COFCO Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

High number of new and inexperienced directors

COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt

First quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.001 in 1Q 2023)

COFCO Biotechnology Co., Ltd., Annual General Meeting, May 16, 2024

Returns On Capital Signal Tricky Times Ahead For COFCO Biotechnology (SZSE:000930)

COFCO Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

COFCO Biotechnology Co., Ltd.'s (SZSE:000930) Price Is Right But Growth Is Lacking

COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.097 in 3Q 2022)

COFCO Biotechnology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.23 profit in 2Q 2022)

COFCO Biotechnology Co., Ltd. Implements Cash Dividend (A shares) for 2022, Payable on July 03, 2023

COFCO Biotechnology Co., Ltd. Approves the Election of Wang Laichun as a Non-Employee Supervisor

Full year 2022 earnings released: EPS: CN¥0.57 (vs CN¥0.61 in FY 2021)

Price target increased to CN¥13.68

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.097 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.19 in 2Q 2021)

COFCO Biotechnology Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 10 June 2022

COFCO Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2021

COFCO Biotechnology Co., Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CN¥13.68

High number of new and inexperienced directors

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.091 in 3Q 2020)

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.14 in 2Q 2020)

Cofco Biotechnology Co., Ltd. Approves Final Cash Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥0.32 (vs CN¥0.32 in FY 2019)

Investor sentiment deteriorated over the past week

New 90-day high: CN¥10.11

Investor sentiment improved over the past week

New 90-day high: CN¥9.64

Third quarter earnings released

COFCO Biotechnology Co., Ltd. to Report Q3, 2020 Results on Oct 26, 2020

First half earnings released

New 90-day high - CN¥11.13

COFCO Biotechnology Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥8.19

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines